.Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AC18_Indacaterol.Indacaterol .Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AC18_Indacaterol.Indacaterol| name: | Indacaterol |
| ATC code: | R03AC18 | route: | inhalation |
| n-compartments | 2 |
Indacaterol is a long-acting beta2-adrenergic agonist (LABA) indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is inhaled once daily as a bronchodilator and is approved for clinical use in many countries.
Pharmacokinetic parameters reported in healthy adult volunteers, both male and female, after single and multiple-dose inhalation.
Demin, I, et al., & Sechaud, R (2016). Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients. International journal of clinical pharmacology and therapeutics 54(6) 405–415. DOI:10.5414/CP202558 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27049057
Bartels, C, et al., & Vaidya, S (2021). Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler. European journal of drug metabolism and pharmacokinetics 46(4) 487–504. DOI:10.1007/s13318-021-00689-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/34024035
Hosoe, M, et al., & Kramer, B (2011). Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies. Clinical drug investigation 31(4) 247–255. DOI:10.2165/11586520-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21184620